Sage Therapeutics

Human brain
#Mergers and acquisitions #Neuropsychiatric disorders #Neuroscience #Postpartum depression #Sage Therapeutics #Supernus Pharmaceuticals

Supernus acquires Sage to strengthen neuropsychiatry portfolio

Supernus Pharmaceuticals will acquire Sage Therapeutics through a tender offer totalling approximately $795 million.  The transaction will provide Supernus with Zurzuvae (zuranolone) capsules CIV, the only US Food and Drug Administration (FDA)-approved oral medicine indicated for the treatment of adults with postpartum depression.  Through a… Read More

#Business & Investment #News #Trending News

Patient speaking to psychiatrist
#FDA #Mental health #Postpartum depression #Sage Therapeutics

First oral drug for postpartum depression approved in US

The US Food and Drug Administration (FDA) has approved Sage Therapeutics’ Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health… Read More

#News #Regulatory